open access

Vol 5, No 3 (2009)
Review paper
Published online: 2009-05-15
Get Citation

The principles of the therapy of primary cutaneous lymphomas

Robert Gniadecki
Onkol. Prak. Klin 2009;5(3):103-108.

open access

Vol 5, No 3 (2009)
REVIEW ARTICLES
Published online: 2009-05-15

Abstract

Cutaneous lymphomas present with the mature T-cell (> 70%) or the B-cell phenotype. Primary cutaneous lymphomas are those manifesting clinically in the skin before an eventual lymph node or organ involvement. The therapy of cutaneous lymphomas needs an interdisciplinary approach involving dermatology, oncology and haematology. In the present WHO-EORTC classification of cutaneous lymphomas there are 19 well-defined entities among which mycosis fungoides is the most prevalent. Mycosis fungoides is an indolent, chronic lymphoma, which should primarily be managed by skin-directed therapies (phototherapy, radiotherapy), sometimes in combination with interferon or bexarotene. In more advanced stages tumor debulking or palliation can be achieved by chemotherapy. Treatment of aggressive T-cell lymphomas is difficult and systemic multiagent chemotherapy and allogeneic bone marrow transplant have been used. Cutaneous B-cell lymphomas are in most cases indolent and can easily be managed by radiotherapy.

Abstract

Cutaneous lymphomas present with the mature T-cell (> 70%) or the B-cell phenotype. Primary cutaneous lymphomas are those manifesting clinically in the skin before an eventual lymph node or organ involvement. The therapy of cutaneous lymphomas needs an interdisciplinary approach involving dermatology, oncology and haematology. In the present WHO-EORTC classification of cutaneous lymphomas there are 19 well-defined entities among which mycosis fungoides is the most prevalent. Mycosis fungoides is an indolent, chronic lymphoma, which should primarily be managed by skin-directed therapies (phototherapy, radiotherapy), sometimes in combination with interferon or bexarotene. In more advanced stages tumor debulking or palliation can be achieved by chemotherapy. Treatment of aggressive T-cell lymphomas is difficult and systemic multiagent chemotherapy and allogeneic bone marrow transplant have been used. Cutaneous B-cell lymphomas are in most cases indolent and can easily be managed by radiotherapy.
Get Citation

Keywords

primary cutaneous lymphomas; therapy; phototherapy; bexarotene; interferon; guidelines

About this article
Title

The principles of the therapy of primary cutaneous lymphomas

Journal

Oncology in Clinical Practice

Issue

Vol 5, No 3 (2009)

Article type

Review paper

Pages

103-108

Published online

2009-05-15

Bibliographic record

Onkol. Prak. Klin 2009;5(3):103-108.

Keywords

primary cutaneous lymphomas
therapy
phototherapy
bexarotene
interferon
guidelines

Authors

Robert Gniadecki

References (8)
  1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10): 3768–3785.
  2. Olsen E, Vonderheid E, Pimpinelli N, et al. ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110(6): 1713–1722.
  3. Kim YH, Willemze R, Pimpinelli N, et al. ISCL and the EORTC. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007; 110(2): 479–484.
  4. Senff NJ, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br J Dermatol. 2007; 157(6): 1205–1211.
  5. Trautinger F, Eder J, Assaf C, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. Eur J Cancer. 2006; 42(8): 1014–1030.
  6. Dummer R, Assaf C, Bagot M, et al. Maintenance therapy in cutaneous T-cell lymphoma: who, when, what? Eur J Cancer. 2007; 43(16): 2321–2329.
  7. Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008; 41(7): 597–604.
  8. Senff NJ, Noordijk EM, Kim YH, et al. European Organization for Research and Treatment of Cancer, International Society for Cutaneous Lymphoma. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood. 2008; 112(5): 1600–1609.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl